Several preclinical studies have demonstrated PD-L1 expression status in human glioma tissues [11, 16]; however, evidence of the efficacy of PD-1/PD-L1 antibody immunotherapy in glioblastoma is limited. The gene discussed is CD274; the disease is central nervous system cancer.